$PTN Boehringer Ingelheim lost more than $500m developing “Girosa” as it was then known. He said in a talk that they wish they had pulled the plug much earlier. Second thoughts... Now comes along vyleesi which works very well, and works on men as well. Just what they failed to do with Girosa. Think they don’t want a second shot at this market. Think again. Vyleesi could easily do Viagra numbers in the stable of the right Pharma Co. They probably want PTN’s pipeline too.